Inulin Composition Polymerization Profile for Sinusitis Prophylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing prophylactic means are insufficient to prevent sinusitis, particularly in children aged 3 to 6 years, despite efforts to reduce upper respiratory tract infections.
Innovation Solution
An inulin composition comprising 25 to 40 wt.-% of compounds with a degree of polymerization (DP) ≥11 and 15 to 30 wt.-% of Fm compounds with m=2 to 9, having a number-average degree of polymerization (DPAV) of 6.5 to 9, is used to decrease the risk of sinusitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional prophylactic means (behavioral instructions, immune-stimulants, probiotics) are used, then some protective effect against sinusitis is achieved, but the effectiveness is insufficient to significantly reduce sinusitis incidence
Solution Approach 1:
The patent changes the chemical parameters of the inulin composition by specifying precise ranges for degree of polymerization (DP≥11 compounds at 25-40 wt.-%, Fm compounds with m=2 to 9 at 15-30 wt.-%) and number-average degree of polymerization (DPAV of 6.5 to 9), creating a optimized prebiotic composition that significantly outperforms conventional prophylactic means in reducing sinusitis incidence
Solution Approach 2:
The patent creates a composite prebiotic composition combining different inulin fractions (GFn- and Fm-compounds) with specific molecular weight distributions to achieve synergistic effects that enhance immune system performance and reduce sinusitis risk more effectively than single-component probiotics or conventional treatments
2Reliability
If probiotics are administered to reduce upper respiratory tract infections, then some preventive effect is achieved, but large numbers (billions) of living bacteria must be administered daily to ensure continuous colonization
Solution Approach 1:
The patent replaces living probiotic bacteria (which require continuous daily administration of billions of units to maintain colonization) with inulin prebiotics that can be administered as a stable, non-living substance, eliminating the need for continuous high-dose replenishment while maintaining preventive effects against sinusitis
Solution Approach 2:
The patent uses inulin prebiotics as an intermediary substance that supports and modulates the host's endogenous microbiota and immune system, rather than relying on direct colonization by exogenous probiotic bacteria, thereby achieving preventive effects with simpler administration
3Reliability
If antibiotics are used to treat bacterial sinusitis, then infection is eliminated, but up to 75% of all antibiotic use in high-income countries is for acute upper respiratory tract infections, contributing to antibiotic resistance
Solution Approach 1:
The patent applies prebiotic inulin supplementation as a preliminary preventive measure to modulate the immune system and microbiota before sinusitis occurs, reducing the incidence of acute upper respiratory tract infections and thereby preventing the need for antibiotic treatment and the associated development of antibiotic resistance
Data Source
AI summary
The present invention relates to an inulin composition comprising GFn- and Fm-compounds, in particular for decreasing the risk of sinusitis, preferably for use in the prophylaxis of sinusitis in a subject in need thereof and food, beverages and pharmaceutical compositions containing the inulin composition.